Unresectable Gastroesophageal Junction Adenocarcinoma Recruiting Phase 2 Trials for Balstilimab (DB15676)

IndicationStatusPhase
DBCOND0113409 (Unresectable Gastroesophageal Junction Adenocarcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06251973A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerTreatment